Food&Health

Healthier Choices Management Corp (OTCMKTS:HCMC) Stock Sees High Volume: Now What?

Healthier Choices Management Corp (OTCMKTS:HCMC) Stock Sees High Volume: Now What?

Although the market was largely flat on Monday, the Healthier Choices Management Corp stock emerged as one of the few exceptions. Investors flocked to the stock in a big way yesterday and that saw the Healthier Choices Management Corp (OTCMKTS:HCMC) stock ending up with strong gains.

There was no news about the company yesterday but it is clear that investors may have found something that instigated them to get into the stock yesterday. It should be noted that the move in the Healthier Choices Management Corp stock yesterday turned the stock into a ‘double zero’ stock from a ‘triple zero’ stock. Despite the rally in the stock yesterday, it should not be forgotten that the stock has experienced considerable volatility in recent weeks due to the situation with its patent infringement lawsuit with tobacco giant Phillip Morris.

The positivity around the stock may be actually related to the patent infringement lawsuit. Although a court had granted Phillip Morris’ motion to dismiss the case, Healthier Choices had the option of filing for an amended complaint, and this past Friday the company did take up this option.

The patent infringement lawsuit is related to the IQOS device and it has been alleged that the combustion electronic pipe actually infringes on a patent held by Healthier Choices. After the filing of the new complaint, investors are possibly feeling a lot more positive about the community. It now remains to be seen if the Healthier Choices stock can hold on to this momentum and end up adding to its gains.

read more
Healthier Choices Management Corp (OTCMKTS:HCMC) Stock Sees Buying Interest At Lower Level

Healthier Choices Management Corp (OTCMKTS:HCMC) Stock Sees Buying Interest At Lower Level

It was a pretty difficult time for Healthier Choices Management Corp (OTCMKTS:HCMC) as its patent infringement case against tobacco giant Phillip Morris USA was dismissed by the court.

The District Court for the Northern District of Georgia granted Phillip Morris USA’s motion to dismiss the patent infringement case and it came as a severe body blow to Healthier Choices Management. While the stock dropped after the announcement, the situation has changed for the company this week.

The Healthier Choices Management stock has gone off the blocks fairly strongly this morning and has managed to clock gains of as much as 23% already. In this sort of situation, it may be necessary for investors to take a closer look at the decision from the court last week.

At the time it was announced that Healthier Choices Management had fourteen days within which it could file another complaint but after suitable amendments. The company had already announced last week that it was going to file an amended complaint. Over the past months, there had been considerable focus on this patent infringement lawsuit among investors.

There had also been considerable internet chatter about the possibility of a large settlement and such speculation had also resulted in the Healthier Choices Management stock making considerable gains. It is unclear why the stock has rallied this morning but it could be a good idea for investors to keep an eye on the stock and also on the news wires with regards to any specific news.

read more
Is Healthier Choices Management (HCMC) Stock a Good Buy After The Big Fall?

Is Healthier Choices Management (HCMC) Stock a Good Buy After The Big Fall?

Over the course of the past months, there had been a certain degree of excitement about the patent infringement lawsuit that had been filed by Healthier Choices Management Corp (OTCMKTS:HCMC) against tobacco giant Phillip Morris USA Inc.

However, the Healthier Choices suffered a major setback yesterday after the motion to dismiss the lawsuit by Phillip Morris USA and Phillip Morris Products SA was granted by the District Court for the Northern District of Georgia. The possibility of a large settlement had caused a lot of buzz around the Healthier Choices stock and driven a certain degree of speculation as well. The decision from the court yesterday came as a significant blow to the company’s stock and it tanked by as much as 17%.

It is now going to be interesting to see if the stock can make a quick recovery or not. In this regard, it might be a good idea for investors to keep in mind that all is not lost for Healthier Choices. The court has actually given the company a period of 14 days within which it can submit an amended complaint against Phillip Morris USA.

The company notified that it is going to take up the option and submit such a complaint before the deadline. Last week the company had been in the news after it announced that it was awarded a United States patent for the Electronic Vaporizer Cartridge with Encased Heat Source. The encasing of the cartridge with non-reactive materials is meant for promoting safe vaping.

read more
Collection Sites Launches Business to Business Sales Initiatives – Provides Update With February Sales of 30,717 Tests at an Average Price of $98 per Test

Collection Sites Launches Business to Business Sales Initiatives – Provides Update With February Sales of 30,717 Tests at an Average Price of $98 per Test

Read original article here.

Collection Sites launched multi-week custom testing solutions for a high-school athletics department in Redlands, California and a film production company in Los Angeles as part of its new business-focused sales strategy. Further, Medivolve announces an investor webinar Tuesday, March 23rd at 1 pm ET

TORONTO, March 18, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to provide investors with a sales update and announces the launch of a new business to business sales strategy, including the initiative of two custom testing solutions.

On Monday, March 8th, 2021, Collection Sites launched two multi-week custom COVID-19 testing programs as part of its new business-focused testing services. Moving forward, Collection Sites will be dedicating additional efforts to securing testing contracts with businesses across the United States to provide custom testing solutions.

The first program is with a TV & Film production studio based in Los Angeles, where Collection Sites staff provide 24 hour PCR test results on-site for crew, talent and staff in accordance with the required COVID-19 testing policies. The testing program will last four weeks, with approximately 500 PCR tests expected to be completed.

The second program is with the athletics department of a school district in Redlands, California. Collection Sites will supply and conduct on-site rapid antigen tests on students, athletes, and staff as required by the athletics department. The testing program will last until the end of June 2021, where up to 3,750 rapid antigen tests can be completed over the period.

February Sales

During the month of January, the Company realized the sale of 30,717 tests at an average sale price of $98 per test across its network. Approximately 59% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

“In February we saw another solid month of sales with over 30,000 tests conducted across our network. While we experienced some operating challenges due to winter weather, particularly in Texas and along the east coast during the month, we are still very happy with the sales results,” commented Medivolve CEO Doug Sommerville. “As vaccination efforts rollout, we anticipate retail demand to soften and as such are turning to exciting new sales initiatives focused on custom testing solutions for businesses. While COVID cases have receded across America, we believe the need for proper testing will remain for the foreseeable future. This also highlights the strategic importance of our telehealth initiatives and the launch of a disruptive and sustainable business model that helps to provide accessible and convenient medical services to our patients.”

Upcoming Corporate Webinar

Medivolve is pleased to announce it is hosting a Corporate Update webinar, on Tuesday, March 23rd at 1 pm ET that will provide investors with an update on the Company’s recent business developments.

Registration Link: https://us02web.zoom.us/webinar/register/WN_tmyDKJWYQTGoviFFM1zq7Q

Specifically, the webinar will feature Medivolve CEO Doug Sommerville and Dr. Glenn Copeland to elaborate on Collection Sites’ telehealth strategy. Dr. Glenn Copeland is a medical advisor to Medivolve and CEO of Glenco Medical, a Medivolve partner company. With Dr. Copeland’s guidance, Medivolve and Collection Sites are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.

About the Collection Sites

The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The key to flattening the curve is to increase testing.

The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.

About Medivolve Inc.

Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas: prevention, detection, and treatment.

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments to be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, [email protected]

For investing inquiries please contact:[email protected]

For US media enquires please contact:Veronica [email protected]

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to sales results; the proposed roll-out of business testing; the Company’s expansion into telehealth; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

read more
Medivolve Signs Agreement to Acquire 100% of Modern Rx LCC, a Las Vegas based Pharmacy

Medivolve Signs Agreement to Acquire 100% of Modern Rx LCC, a Las Vegas based Pharmacy

Read original article here.

As part of its telehealth strategy, Medivolve has acquired a pharmacy to better serve Collection Sites telehealth patients as the program launches. Further, Medivolve will host an investor webinar Tuesday, March 23rd at 1 pm ET

TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce the signing of a binding Letter of Intent (LOI) to acquire a 100% equity interest in Modern Rx LLC, a Las Vegas based pharmacy from shareholders of Modern. This pharmacy is expected to serve as an important component of Medivolve’s telehealth strategy, where Collection Sites telehealth patients will be able to have their presecription filled directly through the pharmacy’s operating license.

“As Medivolve developed its telehealth strategy, we saw the need for the ability to fill patients prescriptions directly. As such, management sought out an operating pharmacy that would imemdiatley allow Collection Sites to offer valuable telehealth services to patients when the program launches,” commented Medivolve CEO Doug Sommerville. “The Modern Rx company provides Medivolve with the necessary licensing and infrastructure at a price that is accretive for shareholders. As Medivolve’s telehealth program launches, we anticipate the additional services offered through Modern Rx, and its network of pharmacy relationships nationally, will be an integral component of the telehealth solution.”

About the Transaction

Medivolve will acquire a 100% equity interest in Modern from the shareholders of the company. As consideration for the acquisition of a 100% equity interest in Modern, Medivolve shall pay to the Modern shareholders: (i) cash consideration of US$100,000; and (ii) one (1) million common shares of Medivolve. The completion of the transaction to acquire 100% of Modern Rx LLC is subject to customary closing conditions, including due diligence to the satisfaction of Medivolve, the parties entering a definitive agreement and NEO Stock Exchange approval. No finder fees are payable in connection with, and no change of control of Medivolve will result from, the transaction.

Upcoming Corporate Webinar

Medivolve is pleased to announce it is hosting a Corporate Update webinar, on Tuesday, March 23rd at 1 pm ET that will provide investors with an update on the Company’s recent business developments.

Registration Link: https://us02web.zoom.us/webinar/register/WN_tmyDKJWYQTGoviFFM1zq7Q

Specifically, the webinar will feature Medivolve CEO Doug Sommerville and Dr. Glenn Copeland to elaborate on Collection Sites telehealth strategy. Dr. Glenn Copeland is a medical advisor to Medivolve and CEO of Glenco Medical, a Medivolve partner company. With Dr. Copeland’s guidance, Medivolve and Collection Sites are developing telehealth plans that include remote patient monitoring and virtual care, among other offerings. Collection Sites intends on leveraging its network of sites and large customer database to market these new services and launch a series of mobile clinics.

About the Collection Sites

The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.

The key to flattening the curve is to increase testing.

The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.

About Medivolve Inc.

Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:4NC) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Medivolve’s primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

For additional information, please contact:

Doug Sommerville, CEO [email protected]

For investing inquiries please contact: [email protected]

For US media enquires please contact: Veronica Welch [email protected]

Cautionary Note Regarding Forward-looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the expansion of COVID-19 testing sites; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

read more
Medivolve Inc. (OTC-COPRF, NEO-MEDV) is Possibly Ready for a Big Move

Medivolve Inc. (OTC-COPRF, NEO-MEDV) is Possibly Ready for a Big Move

Medivolve Inc. (OTC-COPRF, NEO-MEDV) is possibly ready for a big move, traders place this on your watchlist immediately!

 Here are SIX reasons why Medivolve is just warming up!

  1. The chart is potentially very promising.
  2. The Testing Network is established and nation-wide.
  3. Covid is here to stay!
  4. Recent press releases are incredible!
  5. Medivolve (COPRF/MEDV) is poised to be a major disrupter of medical services due to their low CPA (Cost Per Acquisition).
  6. A leader is a dealer in hope and the leadership team embodies hope for traders!

Medivolve

Company Name: Medivolve, Inc.

Ticker: (OTC-COPRF, NEO-MEDV)

52 Week High: $.67

Current Trading Price: $.32

Market Trend: Bullish

Company Summary:  Medivolve, Inc. has a substantial collection of leased sites for COVID-19 testing, offering convenient access to rapid antibody and antigen tests; these tests take 8-10 minutes to administer, provide results in less than 24 hours and cost under $100 along with standard PCR tests. The company is expanding into tele-health and tele-diagnostics which they intend to capture a significant market share through their impressive CPA model for obtaining new clients, where they can disrupt the medical service industry with hundreds of convenient walk up locations rather than the traditional come and wait in a Covid-19 saturated doctors lobby for your hour late appointment. 

The chart is potentially very promising!

February 04, 2021 

In order to maximize operational efficiency, Collection Sites is conducting a state by state expansion where possible. The new sites are currently located on the properties of Simon’s Property Group, an investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed-use destinations and an S&P 100 company as well as Sandor Development Group. Additional sites are expected to be open in Texas, Florida, and Georgia within the coming weeks.

November 11th – Collection Sites Announces Agreement to Offer COVID-19 Testing Services and Protocols for The Elf On The Shelf’s Magical Holiday Journey

November 17th – QuestCap Announces Planned Name Change to Medivolve Along With Transition to Single Purpose Medical Company

December 1 – Collection Sites Expands Convenient COVID-19 Testing Across America with 25 Additional Testing Sites

January 5th 2021 – Medivolve (COPRF/MEDV) announces a C$5M bought deal private placement led by Canaccord Genuity.

Medivolve entered into an agreement with Canaccord Genuity Corp., on behalf of a syndicate of underwriters (collectively the “Underwriters”), pursuant to which the Underwriters have agreed to purchase on a bought deal private placement basis, 20,000,000 units of the Company (“Units”) at a price of C$0.25 per Unit (the “Issue Price”), for aggregate gross proceeds of C$5,000,000

The press releases over the last three months have garnered serious attention by Wall Street, take a look at this CHART.

Medivolve Chart 1

The chart above is potentially very promising with some serious consolidation taking place over the last month. Out of the first 34 volume bars on this chart 24 are green, closing positive for the day, which represents 71% positive days. Hence, the stock reacted with an ascending, bullish, chart line. 

The run started on 11/27/2020 at a price per share of $.125 and due to those “buying” days it reached a high of $.60 on 1/20/21 which represents a 380% gain over the specified period. 

Now let’s look at the consolidation that took place after the amazing run of 380% gains, there were 22 volume bars after the run to $.60 with 13 representing a sell off day, 60%, hence the traders who were happy with their gains from the run exited their positions. This is consolidation, which creates a prime environment for another massive possible price increase due to the lack of sellers creating downward pressure. 

In short, many people bought the COPRF/MEDV on the two month run to $.50-$.60 then sellers started to exit their positions creating downward pressure resulting in the share price falling from the high of $.60 down to $.33. Moreover, $.33 still represents a 164% gain from the November price of $.125 which reveals this stock could be primed for another move holding a much higher main trend line than November!

This channel is poised for a possible major breakout!

Medivolve Chart 2

Let’s review the 5 day chart and one can see the channel-line, top line, and the main trend, bottom line, is a perfect set up for a possible strong run. What does that mean? A bullish channel traditionally signals technical traders to watch or buy a stock based on the ascending main trend line and the corresponding channel-line. 

The Testing Network is established and nation-wide!

Medivolve has signed with a major multi-billion dollar premium mall operator to set up these  Collection Sites COVID-19 testing centers to offer convenient access to rapid antibody and antigen tests – which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR. The testing centres are powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. 

All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.

Medivolve (COPRF/MEDV) issues Huge News in regards to strategic partners, who will be next?

Medivolve Chart 3

Covid is here to stay!

Feb 3rd, just a few weeks ago, had the third largest amount of cases of Covid-19 in the United States.

Think about this, they made $7.1M in just January and that was just a few months of the company being in business! What will Q2 look like?

During the month of January, the Company realized the sale of 73,973 COVID-19 tests at an average sale price of $96 per test across it’s expanding network. Approximately 52% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

So, the question is, how long will Covid testing be a viable source of income?

The answer: Covid is unfortunately here to stay!

Let’s look at the latest numbers:  Are we going up? Are we holding the average? Or going down?

Almost 71,000 new cases of COVID-19 were reported in the United States on February 22, 2021. 

If those numbers hold true, there will be 2,130,000 new cases (71,000 X 30 days) that have to be tested to be confirmed. Let’s look at the last 13 months to see if the Feb 22 numbers are going up, holding the average or going down.

Between January 20, 2020 and February 22, 2021 there have been almost 28 million confirmed cases of COVID-19 which means that the monthly average is 2,153,000 (28 million / 13 months)  which is almost exactly at the projected average derived from the Feb 22 numbers, which means we are 100% still in the grips of this deadly virus.

Recent press releases are incredible!

February 4, 2021

Sales of 73,973 Tests at $96 , that is over $7M in just January!

During the month of January, the Company realized the sale of 73,973 COVID-19 tests at an average sale price of $96 per test across it’s expanding network. Approximately 52% of the sales were cash pay, with the balance as insurance sales. The Company continued to see the strongest demand for antigen tests, followed by antibody and then PCR.

“We are thrilled by the strong sales performance in the month of January and are excited for future sales with the rapid growth of our network,” commented Collection Sites.

As we already examined above, the Covid numbers are holding to the 13 month average, so the $7.1M in revenue for Medivolve should be a solid projection for the near future. Possibly, as Americans grow tired of masks, quarantines and become lackadaisical in conjunction with warmer weather, get-togethers both public and private, we believe the covid cases will be on the rise as well.

February 18, 2021 

Medivolve Announces Launch of Investor Awareness Campaign

As a trader, I absolutely love seeing emerging companies paying for awareness campaigns. If a company believes in it’s product/service and is willing to have skin in the marketing game, well, it is a very good sign. Medivolve has contracted with three of the most respected investor relations firms in the country:  EMC Marketing Services, Winning Media Marketing Services & Amherst Baer Marketing Services. 

These three firms are savants when it comes to creating awareness around some of the biggest investments in the last decade. Let’s get ready fellow investors, this could be a legendary ride! One of those war stories you tell on your front porch, all eyes on you, hanging on every word as you hear exclaimed, “get out of here, no way!” Let’s take a good look at the companies and monies spent over the duration.

EMC Marketing Services

Medivolve entered into an agreement for electronic media and webcast services, design, development and dissemination services with Emerging Markets Consulting LLC (EMC), with respect to EMC providing investor relation services to the company. Effective February 24, 2021, the EMC agreement has an initial term of 90 days, wherein the company will pay EMC a non-refundable fee of US$250,000.

Winning Media Marketing Services

Medivolve entered into an agreement for strategic digital media services, marketing and data analytics services with Winning Media LLC (WM). Effective February 8, 2021, the WM agreement has an initial term of 90 days, wherein the company will pay WM a non-refundable fee of $250,000. 

Amherst Baer Marketing Services

Medivolve has retained Amherst Baer Consultancy Corp. (ABCC) of Langley, B.C., as investor relations consultant to prepare a marketing campaign for the company. ABCC will be paid $70,000 a month for a three-month contract.

Medivolve (COPRF/MEDV) is poised to be a major disrupter of medical services due to their low CPA of customers

Let’s take a look at the Tele-Health & Tele-Diagnostic Industry

In a press release dated February 22nd, 2021 Medivolve has “A large network of Collection Sites and intends on leveraging its network and large customer database to market these new services and launch a series of mobile clinics.”

What is Tele-Health?

The Health Resources Services Administration defines telehealth as the use of electronic information and telecommunications technologies to support long-distance clinical health care, patient and professional health-related education, public health and health administration. Technologies include videoconferencing, the internet, store-and-forward imaging, streaming media, and terrestrial and wireless communications. Link

What is the Tele-Health market size?

The telehealth market growth will increase by $95.72 billion during 2019-2024. Link 

Why should Medivolve enter into this vertical?

First and foremost, they are mitigating the risk if Covid-19 is eradicated then they will have an established vertical to monetize with their current customer base. The announcement by Medivolve to enter into the TeleHealth sector makes a lot of sense due to their existing customer base, strategic partnerships and to develop an exit strategy when Covid numbers go down. Well done, well done!

CPA, not the accountant, Cost Per Acquisition, it’s the name of the game!

I remember an interview with ClickFunnels’ Russel Brunson and I will never forget it; he said, the name of the game is being able to pay a higher price for a client than your competition. So, if you can create a higher AOV (Average Order Value) then, you can pay more to acquire the client. If you are scaling and penetrating the market enough you can actually start eliminating weak competitors by cutting off their ability to acquire clients by increasing the CPA. It’s reminiscent of Genghis Khan’s legendary military tactic of disrupting the food supply and starving out your enemies. I’m not alluding to Medivolve engaging in such practices but with their massive customer database already acquired to repurpose that database to create new revenue streams would create a massive competitive advantage!

They don’t have to go pay per clicks, hire an agency or pay for a team of sales reps to ring doorbells, they already have a list of thousands of clients who prefer to conveniently walk up to a testing facility on their way to Target. I imagine the client after 8 minute experience said, I sure wish all medical experiences were like this! They will tap into this customer list and it should be even bigger than their current operations!

“A leader is a dealer in hope.” —Napoleon Bonaparte

You’re only as good as your people, let’s take a look. 

Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.  This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

Doug Sommerville is a veteran leader in the North American medical, pharmaceutical and technology industries. Prior to joining Medivolve, Mr. Sommerville held the role of Head of Country for Canada for Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva”), the world’s leading provider of generic medicines. In this role, Mr. Sommerville was responsible for Teva’s third largest global subsidiary, with sales in excess of $1.3 billion. Douglas led all aspects of the company’s commercial, distribution, demand planning and customer operations – aligning and coordinating all company functions, production, supply chain, regulatory and global support functions. Douglas was also the Chairman of the Canadian Generic Pharmaceutical Association up until his retirement from Teva Canada in 2018.

Previous to his tenure at Teva Canada, Mr. Sommerville was Global Vice President, Infusion Systems with Baxter Healthcare International (“Baxter”), one of the world’s largest medical, pharmaceutical and technology companies. In his role, Douglas was responsible for the company’s infusion pumping devices and intravenous administration sets worldwide, as well as pain management and ambulatory infusion devices, working with Baxter’s product development, regional sales and marketing teams globally.

Lawrence Steinman, MD  is Professor of Neurology, Neurological Sciences and Pediatrics at Stanford University and Chair of the Stanford Program in Immunology from 2001 to 2011. His research focuses on antigen specific tolerance in autoimmune disease and in gene therapy for degenerative neurologic diseases. He has elucidated what provokes relapses and remissions in multiple sclerosis (MS). He is taking forward a pivotal clinical trial with antigen specific tolerization therapy for type 1 diabetes. He serves as attending neurologist at Stanford’s Lucille Packard Children’s Hospital.

Steinman was senior author on the 1992 Nature article that led to the drug Tysabri, approved for MS and Crohn’s disease. Tysabri has been taken by over 200,000 individuals with MS.

Dr. Glenn Copeland possesses over 45 years of experience in both orthopaedic treatment and sports medicine, Dr. Glenn Copeland is one of North America’s most prominent foot and ankle specialists.

He has established unique and authoritative treatments specializing in both surgical and non-surgical procedures of the foot and ankle.

Dr. Copeland has founded and directed several highly successful medical companies including Footmaxx Inc., which converted orthopaedic evaluation of the lower extremity from moulding technology to pressure and motion mapping. Dr. Copeland was successful in opening over 1,880 clinics globally.

Between 2002 and 2008, Dr. Copeland was selected to be the founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is universally regarded as one of the top three medical institutions in the world.

He was recruited in 2008 by Mount Sinai Hospital in Toronto to establish the Rehab and Wellbeing Centre and Sports Medicine Centre, which continues to thrive, seeing over 10,000 patient visits each year.

These are 5 very good reasons why Medivolve should be on your watchlist. 

  1. The Testing Network is established active and nation-wide massive and growing with hundreds of additional sites.
  2. Covid is here to stay!
  3. Recent press releases are incredible!
  4. Medivolve (COPRF/MEDV) is poised to be a major disruptor of medical services due to their low CPA (Cost Per Acquisition)
  5. A leader is a dealer in hope and the leadership team embodies hope for us traders!

Happy Trading and remember my adage, “Never try to catch a falling knife!”

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Medivolve, Inc. Small Cap Exclusive has been hired by Medivolve, Inc. for a period beginning on March 3, 2021 to publicly disseminate information about (COPRF) via website and email. We have been compensated $50,000 USD. We will update any changes to our compensation.

Read full disclaimer here.

read more
Can You Name the $15 Million Stock with Eyes on a $35 Billion Market

Can You Name the $15 Million Stock with Eyes on a $35 Billion Market

Long-term success on Wall Street is all about getting ahead of the story everyone else will be chasing months or even weeks down the road. That’s why Endra Life Sciences Inc. (NASDAQ-NDRA) has my attention now.

Look at NDRA today and it’s more potential than powerhouse. The company doesn’t even make room for revenue on its quarterly pre-revenue reports yet. It hasn’t sold anything. The profitability that institutional investors demand is probably years away.

On paper, all it has to back up its $15 million market cap is $3 million in cash, miscellaneous other assets and a whole lot of talent and ideas. Big ideas. Many patents were collected over the last five years, 5 others overseas and dozens of others around the world.

Those ideas and the talent to turn them into commercial reality are the important thing about NDRA right now. All in all, they’re why the analysts who know this little company best say it will be worth $5.00 to $6.00 under the right conditions.

The firm with the most bearish take on NDRA just raised its target to $2.75 and left the door open to additional upgrades beyond. That’s pretty big talk for a stock that was trading at $0.65 at the time . . . and even now, after a blockbuster 65% run, remains within sight of a lowly $1.

THE BILLION-DOLLAR OPPORTUNITY

What have the analysts figured out that the market can’t see? Putting the dots together starts with four simple letters: N A S H.

It stands for Non-Alcoholic Steato Hepatitis. It means fat builds up in the liver (steatosis) and starts causing inflammation. In effect, it’s a form of self-inflicted hepatitis. In extreme cases, scarring and cirrhosis follow. It resembles alcoholic liver disease, only without the liquor.

And it’s a silent health epidemic that we know affects 20 million Americans and probably up to 80 million more people carry the fatty markers without knowing. Do the math and it kills more people than coronavirus . . . but because it’s progressive, the longer you have it, the worse your odds get.

NASH is now the top reason people need liver transplants today. Bigger than hepatitis. It can even cause cancer. While there’s no cure right now, Big Pharma has already spent BILLIONS ($1 billion from Gilead alone, and even then, that drug failed) trying to ring that bell. There are literally dozens of hopeful drugs in the clinic now. Most will fizzle out on the road but those that finally make it all the way to FDA approval will share a $35 billion sales jackpot.

Is it any wonder Wall Street goes nuts on the faintest whiff of progress toward a NASH cure? But if you’re curious about where tiny little NDRA fits into the story and how it hopes to compete with just about every ambitious drug company around, stop wondering.

NDRA isn’t racing the giants to a cure. That’s a fool’s game. Instead, management did a little reading between the lines and realized that they can help by coming up with better ways to detect NASH in its early stages.

Detection is essential. And it’s difficult. “Early detection is one of the biggest challenges” because by the time you notice the symptoms, you’re really sick.

Endra Life Sciences

Right now there are really only two ways to test for NASH: 1) a liver biopsy and 2) a full MRI to peek inside the body. The biopsy is invasive and uncomfortable. The MRI is expensive and relies on increasingly irreplaceable helium to run the magnets.

Between Option A and Option B, there’s no easy way to screen for who has NASH and who doesn’t. When you’re looking at a silent and lethal epidemic, it’s a good idea to run as many tests as you can . . . tens of millions just to identify all the people who have the condition now.

So NDRA came up with Option C. and differentiate fat from lean tissues.

Endra Life Sciences

THE NDRA ALTERNATIVE

Because fat is the problem, recognizing it on the scanner is all it takes. You’ve got NASH or you don’t. Follow-up tests can gauge progress or remission once those new drugs hit the market, telling doctors when to prescribe a pill or how to evaluate its effects.

NDRA’s system is proprietary. Only their machines know how to decode the waves and find the fat. The procedure doesn’t require gigantic magnets or rare helium. The machine costs 1/50 of an MRI suite.

And hospitals don’t have to buy an all-new imaging suite to run the test. This system TAEUS sits next to the existing ultrasound and plugs right in. 

Say there are 20,000 radiology labs in the developed world that do ultrasound screens now. NDRA can ultimately gross $1 billion selling them each a $50,000 TAEUS unit. That’s not a bad windfall at all for a company that’s currently valued at $15 million, right? For little NDRA to trade at even 1X that “base addressable market” opportunity, it would need to unlock truly massive upside . . . which would in turn give shareholders who got in early plenty to cheer.

From there, the accounting really adds up. The system can also map temperature in the body to help guide laser- and heat-based surgical procedures. It can track blood flow down to the microscopic level. Ultimately TAEUS has the potential to spot blockages to diagnose and assist treatment of a wide range of conditions. And throughout, NDRA has made sure to keep building in ways to sell disposable equipment and charge licensing fees to people who have already built the machine.

Remember, tens of millions of people in America alone (not even counting the rest of the world) probably have NASH and need to get a definitive diagnosis. Biopsies cost $1,500 apiece. An MRI scan is running close to double that . . . and that’s when the machines are actually working and slots are available! Even if the disposables only cost a few dollars per procedure, we’re looking at real money here.

All in all, management suspects there’s $18 billion to chase. At that point, the multiplier gets vast. Again, NASH is a big problem and big money: here’s a report suggesting that just selling the genetic markers that say you MIGHT get the disease is going to be worth $2 billion a year very soon. People with the markers will still need physical confirmation. That’s where NDRA comes in.

Endra Life Sciences

SOLVING THE BILLION-DOLLAR PUZZLE 

Of course it’s a long way from a $15 million stock with big dreams to the kind of company that can realistically conquer billion-dollar markets. NDRA today reflects reality on the ground today. However, management has done a lot of work paving the road from here to there.

To start, nothing ever happens in healthcare without regulatory approval. NDRA has already gotten clearance in Europe and is now looking to file its 510(k) medical device submission this summer, so the clock is ticking there. If you aren’t familiar with the 510(k) process, it’s a lot faster than what it takes to get a drug approved.

You really just need to prove safety and effectiveness. As long as your system doesn’t hurt people and actually provides the medical benefit you claim it does, the FDA tends to give you the green light to start selling. Historically it takes less than six months, so as long as NDRA makes its 2Q timeline, we can hope to hear back by the end of the year.

But maybe NDRA wants to wait and make sure the application is as strong as possible. A few months ago their research revealed a past FDA decision that might raise the odds of approval as long as they “do it that way.” Getting the data points in line has taken a little more time.

Meanwhile, the Europeans have already signed off on the device. That’s 5,500 hospitals or a $275 million revenue opportunity ($50,000 per TAEUS) that just opened up. Even if nothing happens on other regulatory fronts for months to come, NDRA is now free to start making money. And at this point, any slice of the initial $275 million market will feel mighty good.

Once you get the green light, you still need to convince the doctors they need to lobby hospitals to buy the equipment. NDRA has teamed up with the liver experts at the Medical College of Wisconsin while partnerships with the University of Pittsburgh Medical Center and Rocky Vista University do their share to spread the word. The more data that gets out into the journals, the easier the job gets.

Endra Life Sciences

A lot of doctors are probably eager for an efficient NASH testing system, so resistance is probably going to be mild at worst. When potential customers actively want to buy what you’re selling, all you have to do is give them a way to hand you the money.

And that’s the last big piece of the puzzle snapping into place. NDRA isn’t building a vast sales force to approach thousands of hospitals. That takes time and a whole lot of money. Instead, they’ve teamed up with GE Healthcare . . . which sells and supports the ultrasound machines that TAEUS plugs into.

If the ultrasound is the razor and TAEUS is the fancy new blade, NDRA has made a very powerful friend. GE is happy because the added functionality makes the ultrasound more relevant. NDRA gets to virtually “ride along” on the sales conversations. That’s what “facilitating introductions” means in that last link. Do you have an ultrasound machine? Did you buy it from GE? Have you heard that NDRA can leverage your existing machine to detect NASH?

THE BOTTOM LINE

Add it all up, NDRA has a solid shot at getting a lot of those hospitals to upgrade their existing ultrasound machines. Once they all do it, that’s billion-dollar potential, a real company maker.

Look at a company like Exact Sciences, which makes mail-in colon cancer tests. It took the last two years to book $1.3 billion in sales. This year it might do $1.2 billion as well. That once-obscure company is now worth close to $13 billion.

According to that math, NDRA only needs to sell a couple dozen TAEUS systems a year to justify its current market cap. The European hospitals can buy now. Even if NDRA hits 1% penetration of that market, we’re looking at a lot more than “a couple dozen” sales.

Remember, GE is helping. The data is flowing. Awareness around NASH isn’t fading. Doctors are waking up to the depth of the problem they’re facing as liver cancer and transplant numbers hit the red zone.

Day by day, those hospitals will get more receptive. And then “a couple dozen” will look small, at which point NDRA translates its potential into something a lot more substantial . . . and shareholders who saw the future in an obscure $15 million stock will be able to brag that they were early and right.

Endra Life Sciences

Disclaimer :This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ​​NDRA (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. ​​Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither ​​Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by ​​Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. ​SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, ​SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM ​SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ​SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. By using ​Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.The website contains links to other related World Wide Web Internet sites and resources. ​Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does ​Small Cap Exclusive endorse nor is ​Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall ​Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.You agree to indemnify and hold ​Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.​Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Endra Life Sciences Inc. Small Cap Exclusive has been hired by 1047631 BC LTD for a period beginning on June 18, 2020 to publicly disseminate information about (NDRA) via website and email. We have been compensated $61,000. We will update any changes to our compensation.Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. ​​Endra Life Sciences Inc. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.​Small Cap Exclusive, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

read more
3 Reasons Why You Should Be Watching Rainmaker Worldwide, Inc. (OTC-RAKR)

3 Reasons Why You Should Be Watching Rainmaker Worldwide, Inc. (OTC-RAKR)

“Arguably the most important resource on the planet, water companies have garnered much investor attention, as they grant exposure to a commodity with a completely inelastic demand”

Rainmaker Worldwide, Inc. (OTC-RAKR) takes center stage with explosive gains over the last 2 weeks. We believe this is just the beginning as the general public begins to find out about this amazing company.

It’s quickly becoming no secret that we tapped into something special with Rainmaker as share price continues to rise from just under a penny to hitting a high of $0.248 on Friday showing a gain of 2,380% since it’s trend higher in September.

We released Part 1 on Rainmaker back on Monday titled: Put Rainmaker Worldwide, Inc. (OTC-RAKR) On Your Radar introducing you to this play and to it’s incredibly powerful story early last week, confident that we had something special and our hard work payed off as Rainmaker continued its trend higher trading at $0.14 on Monday and making gains of 77% off its highs on Friday.

Solid support and new base above $0.20

**But before we get into this article, we have to announce Rainmaker’s Breaking News**

Capping off Rainmaker’s marvelous September run is breaking news released just this morning that we have to talk about first as this news is releasing to the public right now.

September 30, 2019: Rainmaker Worldwide Inc. today announced the award of European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. One of 15 winners across all of Europe out of nearly 6000 applicants.

Rainmaker Worldwide Inc. today announced the award of European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. One of 15 winners across all of Europe out of nearly 6000 applicants.

After a two-year process of due diligence by the European Union, Rainmaker was granted a Grant for more than 2.5 million USD to develop a Water to Water solution in the Canary Islands. It will be 100% powered by renewable energy. The only desalination of its kind using only renewable energy.

Get the full news release here.

[thrive_leads id=’8697′]

Well, it appears that we’ve found the smoking gun that we’ve been looking for. It’s no secret that penny stocks can move on just about nothing and if there’s nothing behind the play then, chances are, the move higher was just a blip on the radar. This news is indicative of Rainmaker’s September run from under a penny to nearly a quarter and is also an indicator that these massive percentage gains are here to stay because the gains were founded on strong news from the company.

We’re very thrilled to have been able to time this one correctly and that we were able to get this one out to you all ahead of its breaking news but we were more excited to have the opportunity to present our viewers a company with meaningful purpose. Finally, we have something that’s not just a potentially winning play but also a company that makes you feel good investing in because Rainmaker is tackling humanity’s greatest problem: producing safe drinking water for communities in need so they can thrive and never go thirsty. 

As stated in our first article on Rainmaker, a good story alone doesn’t pay the bills so today, and on top of the breaking news, I’m going to give you three more reasons why we believe that Rainmaker’s September win streak is only just beginning..

But for those of you who missed last week’s article, click here to get up to date or read the following company overview below:

Rainmaker Worldwide, Inc. (OTC-RAKR)   

Rainmaker produces drinking water for communities. It offers water-producing technologies, including air-to-water technology, which harvests fresh water from the air; water-to-water technology that transforms seawater or polluted water into drinking water; and commercial water-to-water technology.

They offer a suite of Air-to-Water and Water-to-Water technologies. These products deliver a better, more economical way to provide safe drinking water. Air-to-Water harvests fresh water from humidity in the atmosphere, while Water-to-Water transforms non-potable (waste, salty, polluted, grey, or brackish) water into safe drinking water.

All can be wind or solar powered, so they leave no carbon traces. There are also options for grid and generator-powered models. All this, at the lowest cost per liter of fresh drinking water on the market.

Alright, let’s get into this one by starting with the massive problem that Rainmaker and others are taking aim to solve.

The Hard Problem of Fresh Water

When it comes to getting fresh, clean, drinkable water to the world, there’s no bigger problem out there and when it comes to entrepreneurs, the bigger the problem, the bigger the opportunity. The first reason why we like Rainmaker is that they’re solving a problem that can offer massive profit to those who can produce low cost per liter fresh drinking water to the market as soon as possible.

The monumental problem: According to the company, with Less than 3% of the world’s water being fresh, more than 800 million people are living without access to a source of safe drinking water. An estimated 5 billion people face water scarcity problems at least one month per year and as world population continues to grow, millions more will experience water stress.

Rainmaker Worldwide, Inc. - RAKR

Wells are running dry as aquifers are being drawn down faster than they are being replenished. In other cases, the water table has been polluted and well water is no longer safe.

Harvesting rainwater is usually supplemental. Many parts of the world experience long dry seasons with little or no rain. Shifting weather patterns make it unreliable.

Desalination at scale has been a technical challenge. Traditional technology is only feasible in large, expensive installations suitable for feeding municipal water systems.

Treating contaminated water has also been a technical challenge at scale. There are numerous technologies for extracting water from humidity. However, most have only been able to achieve this on a personal or household level.

Water scarcity multiplies risk, raising the chances of civil conflict following periods of drought, amongst other problems. The 2016 World Economic Forum’s Report warns that “failure to address climate change and water crises” could also trigger large-scale migrations.” – (https://www.weforum.org/reports/the-global-risks-report-2016)

Lower income countries are most vulnerable as they lack good governance and do not have the resources to invest in water infrastructure.

With nearly 78% of the world’s poor living in rural areas, they are the first and hardest hit by water scarcity, suffering significant income losses. These losses prevent rural families from investing in their children. For example, “Children in Vietnam who experienced these shocks were shown to have delayed school entry, slowed progress in school, and lower height than their peers that did not experience this shock.” – (https://www.governancenow.com/news/regular-story/thirsty-world-stares-limp-economy)

Children in rural India and Mexico were similarly harmed due to water scarcity. – (https://www.governancenow.com/news/regular-story/thirsty-world-stares-limp-economyIncreased water scarcity also spreads disease because of exposure to contaminated water and less water for hygiene. There are longer term effects as well, including causing nutritional deficits in young children which can permanently affect their learning capabilities. – (https://www.who.int/water_sanitation_health/publications/jmp-2017/en/)

Big Time Investors Betting Big On Water

Following big time investors is a tried and true method of finding out where the profitability is located because good investors tend to invest in profitable industries and over the past decade, we’ve seen several big time investors getting into water and that indicates to us that we’ve found a profitable industry to be in.

Whether it’s the Bill & Melinda Gates foundation funneling literally billions into the sustainable sanitation or Warren Buffett buying Nalco, a Chemical Maker and Water Process Technology Company, there’s no question that wealthy investors are getting into water at an alarming rate.

According to an article from globalresearch.ca, (https://www.globalresearch.ca/the-new-water-barons-wall-street-mega-banks-are-buying-up-the-worlds-water/5383274_) investing powerhouses such as Goldman Sachs, JP Morgan Chase, Citigroup, UBS, Deutsche Bank, Credit Suisse, Macquarie Bank, Barclays Bank, the Blackstone Group, Allianz, and HSBC Bank, among others, are consolidating their control over water. 

Wealthy tycoons such as T. Boone Pickens, former President George H.W. Bush and his family, Hong Kong’s Li Ka-shing, Philippines’ Manuel V. Pangilinan and other Filipino billionaires, and others are also buying thousands of acres of land with aquifers, lakes, water rights, water utilities, and shares in water engineering and technology companies all over the world.

Even The Big Short famed Michael Burry, who made his name during the 2008-9 crisis betting against, or shorting, the housing bubble is also focusing all of his trading on water.

Love it or hate it, mega investors are gobbling up this precious resource and following the money trail is a wise bet when looking for a market with long term viability.

Rainmaker Share Price Up 2,380% In September

At the end of the day, share price is, obviously, the most important indicator as to whether a publicly trading company is worth investing in and with Rainmaker’s share price up 2,380% in September, there hasn’t been a more consistently profitable bet that can compare to that growth. In other words, the chart speaks for itself.

Rainmaker Worldwide, Inc. - RAKR

While Rainmaker has been on watch list since the 2017, we have to admit that it wasn’t more than a pipe dream. A hopeful play that we were rooting for because of the help that they could do for the world but nothing anything that we could, in good faith, present to our viewers.

It wasn’t until this one made 1300% gains in over a week of trading before this one indicated to us that this company was worth our immediate attention and it hasn’t shown us any signs of slowing down heading into October. 

Alright, that’s it for this week’s update on Rainmaker, make sure to stay tuned for more news and updates as this one continues to develop.

Disclaimer :This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ​​RAKR (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. ​​Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither ​​Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by ​​Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. ​SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, ​SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM ​SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ​SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. By using ​Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.The website contains links to other related World Wide Web Internet sites and resources. ​Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does ​Small Cap Exclusive endorse nor is ​Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall ​Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.You agree to indemnify and hold ​Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.​Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).We publish the Information on our website, jbnpartners.staging.wpengine.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Rainmaker Worldwide, Inc. Small Cap Exclusive has been hired by Rainmaker Worldwide, Inc. for a period beginning on September 23, 2019 to publicly disseminate information about (RAKR) via website and email. We have been compensated $35,000, and expect to be compensated another $100,000 within the next 60 days. We will update any changes to our compensation.Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. ​​Rainmaker Worldwide, Inc. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.We currently own 150,000 shares of (RAKR) purchased on the open market and intend to sell some or all of these shares on the open market within the next 120 days. We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.​Small Cap Exclusive, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

read more
This is Why Koios is a Leader and Continues with Massive Growth

This is Why Koios is a Leader and Continues with Massive Growth

Ok… We have to start to get serious about a proven industry that’s in the beginning stages of making an extreme change…

Remember about a little over a decade ago when energy drinks exploded overnight and we were seeing new energy drinks coupled with strong marketing seemingly popping up out of nowhere?

You had your Red Bull girls, your Monsters, your Rockstars, your Amps, and a number of other little ones all touting “explosive energy in a can brah!” Whether it was the addictive nature of 200mgs of caffeine and 50gs of sugar per can, the quality marketing, or simply the fact that the big soda staples have been feeding us the same flavord beverage since the early 1900’s, no one could deny that these new drinks were something that the buying population wanted.

These drinks are more expensive than the average carbonated beverage but that didn’t stop consumers from purchasing because these consumers were already looking for a beverage in the healthier direction and boy did these new energy drinks try to market themselves as the new healthier alternative.

Well, ten years later, it’s 2019, the money for the marketing gimmicks has dried up, the taste never improved, and most importantly, the customers have gotten smarter.

The problem for the energy drink industry is that they didn’t deliver on what was potentially a huge chunk of the market. Further, their drinks were essentially sugar and caffeine in a can. They were marketed as being healthier than a can of coke but they weren’t. In many cases, they were worse. And once the consumers figured it out, they left in droves.

But there’s no question that people still want energy in hand. Just go to any Starbucks and see consumer after consumer suck down cup after cup of coffee just to get a hit of it.

Consumers just demanded that the product be healthy, light on the caffeine and sugar, offer brain support, and all around be a drink that boosts performance. – You know, kind of what the energy drinks of the previous decade marketed? – Is that too much to ask?…

Perhaps in 2009, but not anymore…

Enter the world of biohacking and nootropics, which is a class of natural occurring ingredients that switch on your brain and boost mental performance.

Nootropics are supplements that purport to make us smarter. 

Natural nootropics include ingredients like artichoke extract, grape seed extract, ginseng, kava kava, lemon balm, Rhodiola rosea, St John’s wort, yerba mate, caffeine, green tea — substances the U.S. Food and Drug Administration has approved as dietary supplements and classifies as GRAS (generally regarded as safe).

Natural nootropics also include synthetic additives such as choline, griffonia seed extract, theanine, acetyl l-carnitine, B group vitamins, iodine and magnesium just to name a few.

Followers of the nootropic movement, myself included, are adamant of the positive effects. They claim regular consumption could lead to consumers being more alert, getting a boost in memory, increased focus, more creativity, motivation, improved cognitive skills and a better overall outlook on life.

What’s more is that this industry is in the process of pivoting directly into the beverage market at almost exactly the perfect time as a slew of new beverages that contain various combinations of nootropics designed to enhance brain function, with added ingredients that have no jittery side-effects, and, (hint hint) our favorite play has even started the process of adding CBD to further enhance the health experience.

The point is, these beverages are the real deal. They’re everything that the average consumer of more high-end beverages has been hoping for and I believe that these nootropic functional beverages are the future of the entire beverage industry.

Because the fact of the matter is this; beverage companies won’t survive if they ignore the evolution of the consumer for much longer. Consumers are more educated in their dietary choices today and they’ve been on the lookout for healthier beverage alternatives to the high-fructose corn syrup, artificial ingredients, and artificial colors of the beverages of the past.

I mean, what the hell are you putting an ingredient called: Yellow Number 5 into a beverage and actually expect people to drink that trash?

The point here is that this ongoing trend shows us that the beverage industry is ripe for a category killer. 

In fact, according to BevNet, the beverage industry has experienced half a decade-long decline in sales of traditional sugary soft drinks, forcing major beverage companies to look at other beverage companies in search of acquisition to replace their lagging sales.

And we’ve got one such nootropic beverage company at the top of our watch list that has our near complete attention because we believe it to be the one that has the best opportunity to be a category killer in the market.

The company’s name is Koios Beverage Corp. trading on the OTC under the ticker: KBEVF. 

Koios Beverage Corp. develops, manufactures, markets, and distributes nutritional supplements and organic beverages in the United States. It also provides cannabis-infused beverages. As of May 31, 2018, the company had a distribution network of approximately 4,300 retail locations in the United States. It also distributes its products through its website, as well as through other websites.

Due to the functional properties of their nootropic drinks, their lack of the caffeine-crash, and honest to goodness incredible taste, I believe that Koios could become the next big thing in the functional beverage market and eventually displace the old and outdated energy drinks of yesteryear and take the lead in future sales.

They’re already in large retail chain stores such as Walmart and GNC and already have a strong presence on Amazon. They’ve achieved distribution in a total of more than 4,300 stores in less than one year, including 2,910 GNC locations and 1,094 Walmart locations across the United States.

But what truly sets Koios apart from any other functional beverage drink is their creativity and open willingness to invent something truly unique. As of July 19, 2019, through its subsidiary, Cannavated Beverage Corp, Koios has completed development of its CBD-Enhanced functional and began test batch production.

Koios is the real deal and I personally love their drinks. Let’s dive deeper into Koios by going over its key catalysts.

Key Catalysts:

  • The company is making big moves in multiple explosive industries: 
    • The global nootropic market is booming. In 2015, the market was valued at $1.35 billion and is expected to reach over $6 billion by 2024.
      • The market is expanding at a CAGR of 17.9% from 2016 to 2024 according to globalnewswire.com.
    • Koios is also utilizing its subsidiary, Cannavated Beverage Corp by becoming the first “nootropic” beverages enhanced with CBD cannabidiol molecules.
      • The CBD market is expected to hit $22Billion by 2022 according to inc.com.
    • In 2016, while carbonated soft drinks were in the middle of a five-year decline, natural and functional beverages should expect to see a 40 percent dollar growth in the industry according to BevNet.
  • Aggressive Expansion
    • As of early 2019, Koios announced that it signed a vendor agreement with Walmart Inc., and has since been supplying Koios Beverages to 1,094 Walmart locations across the US.
    • Koios also secured an agreement in early 2019 with GNC. According to the agreement, their beverages are now available for purchase in approximately 2,700 GNC retail stores across the US.
    • The company also announced that production is on the rise as the company is currently working to produce 1,000,000 printed KOIOS cans as production levels ramp up to meet the company’s current demands.
  • Excellent Recent News
    • Koios has completed development of its CBD-Enhanced functional and began test batch production on July 19, 2019.
    • Koios also recently provided a very positive corporate update, including:
      • Strong sales numbers
      • Revamped website
      • And the much anticipated Fit Soda launch date, announced above as July 19, 2019.
      • Get the full report here: https://finance.yahoo.com/news/koios-provides-mid-2019-corporate-100000206.html

The Nootropic Market & Functional Beverages

According to the latest report published by Credence Research, Inc. “Nootropics Market – Growth, Future Prospects and Competitive Analysis, 2016-2024,” the global nootropics market was valued at USD 1,346.5 Mn in 2015, and is expected to reach USD 6,059.4 Mn by 2024, expanding at a CAGR of 17.9% from 2016 to 2024.

With expansion projected like that, this is a market that’s worth our attention and we ought to be in the know on all the recent developments in this market as well. This is where Nootropic beverages come in because they are the cutting edge in the Nootropics market.

Nootropic beverages are under the umbrella of the booming multi-billion dollar category of “Functional Beverages.”

A functional beverage is a non-alcoholic drink which provides specific health benefits and contains non-traditional ingredients like minerals, vitamins, herbs, amino acids or added raw fruits.

Basically, it’s a drink augmented with nutrients and/or supplements in order to convey a health benefit to the consumer. Examples of functional beverages include sports and performance drinks, ready to drink (RTD) teas, and nootropic beverages sometimes known as ‘smart drinks’.

Functional drinks are typically more expensive than carbonated beverages due to their shift away from unhealthy and artificial ingredients. However, increasing health awareness in many countries is encouraging consumers to shift from beverages loaded with high-fructose corn syrup, artificial flavors and artificial colors to healthier alternatives in the functional drinks segment, which is expected to boost the demand for the product.

Fit Soda: Koios CBD Enhanced Functional Beverage

As of last week, Koios to Complete Development of CBD-Enhanced Functional Beverage Line: Test Batch Production to Begin on Friday, July 19, 2019 – Get the Full Report Here: https://finance.yahoo.com/news/koios-complete-development-cbd-enhanced-100000708.html

In a press release dated September 4, 2018 , the Company announced its plans to release a functional beverage, which would be infused with CBD to enhance the beverage’s effects and last week test batch production began.

Koios will leverage its existing relationship with Colorado based Keef Brands in the development of this product, with Keef Brands to supply crystalized, water-soluble CBD which will be added to Koios’ existing Fit SodaTM line of functional beverages. 

From the corporate update: The Fit SodaTM beverage product will be produced for nationwide distribution beginning Friday, July 19, 2019 . Koios has received interest in distributing Fit SodaTM from distributors and direct-to-store delivery companies from across the United States. Fit SodaTM will be available in 400 retail stores across the United States no later than the end of September, 2019.

For those of you who don’t know why adding CBD to a functional beverage is such a big deal, check this out: CBD is the non-psychoactive counterpart in cannabis that’s regularly used to treat inflammation, pain, anxiety and epileptic seizures. 

The addition of CBD to Koios’ proprietary stack of nutrients, amino acids, and electrolytes in its Fit SodaTM line of beverages is expected to improve the product’s already impressive effects. 

Pending completion of further testing, the Company also plans to integrate CBD into its KOIOS beverage lineup at a later date. When the proposed beverage is released, Fit SodaTM will be available both with and without CBD.

On Friday, July 19, 2019 , Koios started production of several test batches of its Fit SodaTM product with crystallized CBD supplied by Keef Brands. Upon completion of this production, the Company will be distributing the products from the test batch to select existing clients for trial purposes. 

Feedback derived from these trials will be utilized to further develop the proposed CBD beverage and prepare it for commercial production and distribution under the Fit SodaTM banner.

Large-scale distribution of CBD-enhanced Fit SodaTM will be contemplated by Koios based on feedback that the Company receives from the test batches being produced that began last week.

We are extremely excited to find out how the large-scale distribution works out and will make sure to update you all when it’s released by the company.

More About Koios

For our purposes, the key to the company’s success has been their anti-reliance on caffeine and their focus on ingredients that increase clarity and focus of the mind. 

Koios enhances focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity, and creates all day mental clarity and energy, without using large amounts of stimulants.

And the science is starting to ramp up fast. Just a few months ago, Koios started clinical trials in Denver to prove the testimonials right. “Enhances cognition.” Imagine seeing that on a can in Walmart!

Its core vision is to help a billion people worldwide live more productively through the development of nootropics, which are supplements that improve cognitive abilities.

The company’s flagship product, Koios, is a GMP-certified dietary supplement. Made from natural ingredients and backed by science, Koios is designed to improve focus, memory, mental drive, clarity and energy.

The company produces Koios in the following formulations:

  • Powder supplements containing nootropics as well as caffeine and lion’s mane and chaga mushrooms;
  • Vegan-friendly capsules;
  • Canned beverages containing nootropics along with MCT oil to burn fat and increase metabolism.

Not to be mistaken with prescription-only drugs which are at times used for similar effects, nootropics are over-the-counter dietary supplements; some of which, like Koios, contain ingredients that are currently used in the treatment of patients with Alzheimer’s disease. 

According to media reports, there is believed to be significant and growing use of nootropics among high-achieving students and professionals. The UK’s leading Guardian newspaper found that nootropics are commonly used in Silicon Valley by computer industry professionals who want to “hack” their minds and maximize their productivity without any possible negative effects on the brain.

Koios developed a proprietary nootropic formula that has been shown to enhance brain function including mental focus, memory, and concentration.

Its formula includes superfoods such as lion’s mane mushroom, which contains bioactive substances with beneficial effects on the body, brain, heart, and gut. The Company produces the formula as a line of healthy, organic beverages and drink powders.

Koios has a distribution network of retail locations across the United States including Walmart, GNC and Max Muscle. Together these distributors represent more than 4,300 locations, from sports nutrition stores to natural grocery chains.

Koios also contains the following ingredients, among others:

  • Vitamin B12: Crucial for the function of the nervous system and the synthesis of DNA, B12 also helps in the creation of red blood cells.
  • Vitamin B6: This vitamin is crucial for brain development among children and brain function in adults. B6 is also important in the production of key hormones: serotonin, which regulates mood, norepinephrine, which helps us handle stress, and dopamine.
  • Huperzine A: Developed from the Chinese club moss plant, huperzine A is used on Alzheimer’s patients to boost their memories. It is also used to raise energy levels and alertness and is the subject of medical trials to test its efficacy when combined with other drugs.
  • Bacopa: Also known as brahmi, bacopa is an Indian herb used in Ayurvedic medicine to improve concentration and memory. Modern science has recognized its effectiveness, and it is used to treat symptoms caused by Alzheimer’s disease, ADHD and anxiety.
  • Ciwujia or Siberian ginseng Sports scientists have been interested in this herb since they heard of how mountain climbers in Tibet use it to boost their performance at high altitudes. Peer-reviewed research has shown that this herb has clear positive effects on endurance.

The company’s products can be found online at https://www.mentaltitan.com and in stores, both across the United States and internationally, via a continuously growing distribution network.

Disclaimer :

This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on ​KBEV (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.

​Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. ​​Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither ​​Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by ​​Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.

​​Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.

Information presented by ​​Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

THIS SITE IS PROVIDED BY ​SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. ​SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.

TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, ​SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM ​SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. ​SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.

CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS. 

By using ​Small Cap Exclusive, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.

The website contains links to other related World Wide Web Internet sites and resources. ​Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does ​Small Cap Exclusive endorse nor is ​Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall ​Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.

You agree to indemnify and hold ​Small Cap Exclusive, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.

​Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

​We publish the Information on our website, ​​smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, ​Koios Beverage Corp. ​Small Cap Exclusive has been hired by ​​Koios Beverage Corp.​ for a period beginning on ​May 1, 2018 to publicly disseminate information about (​KBEV) via website and email. We have been compensated $​558,000. We will update any changes to our compensation. We own zero shares of (​KBEV).

Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. ​Koios Beverage Corp. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.

The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.

We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.

The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.

We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.

There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.

We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.

We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.

If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.

The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.

The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.

You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.

When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.

The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.

We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.

If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.

If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.

No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.

​Small Cap Exclusive, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

read more